Key result
Antiplatelet therapy linked to a ~14% reduction in eGFR <30 prevalence in non-dialysis CKD.
Why the study?
Antiplatelet therapy used to prevent cardiovascular events in chronic kidney disease may be associated with bleeding risks, lower efficacy, attenuation of inflammation, and haemogram changes.
Does antiplatelet therapy improve kidney function and lipid profiles in patients with non-dialysis chronic kidney disease?
Cohort (n=170)
Yes
Does antiplatelet therapy improve kidney function and lipid profiles in patients with non-dialysis chronic kidney disease?
Absolute Event Rate: 67.06% vs 77.64%
p-value: p=0.04
Should not yet change practice in non-dialysis CKD; leaves open a potential renoprotective role pending randomized trials.
Antiplatelet therapy used in preventing cardiovascular events in chronic kidney disease may be associated with higher risks of bleeding, low efficacy from fewer occlusive atherosclerotic disease), attenuation of the inflammatory process, and changes in the haemogram. We prospectively determined the kidney function, the haemogram, and the lipid profile of participants with and without antiplatelet therapy. The population with a mean age of 69.21 ± 11.73 years, had more women (65.88%) (P = 0.001).
No takes yet. Share an insight, caveat, or question.
Uduagbamen et al. (2024) conducted a cohort in Non-Dialysis Chronic Kidney Disease (n=170). Antiplatelet therapy vs. Baseline (prior to antiplatelet therapy) was evaluated on eGFR < 30 mL/min (p=0.04). In patients with non-dialysis chronic kidney disease, antiplatelet therapy was associated with a significant reduction in the prevalence of eGFR < 30 mL/min from 77.64% to 67.06% over 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: